may delivered a positive earnings surprise Second Sight Medical Products (NASDAQ:EYES)

0
32

Earnings results for Second Sight Medical Products (NASDAQ:EYES)

Estimate Momentum measures change in analyst sentiment over time and may be an indicator of future price movements. The Change in Consensus chart shows the current, 1 week ago, and 1 month ago consensus earnings per share (EPS*) forecasts. For the fiscal quarter endingJun 2020 , the consensus EPS* forecast has remained the same over the past week at 999 and increased over the past month from -0.41 to 999(243758.54%). none raised and none lowered their forecast. For the fiscal year ending Dec 2020 , the consensus EPS* forecast has remained the same over the past week at 999 and increased over the past month from -1.64 to 999(61014.63%). none raised and none lowered their forecast.

Second Sight Medical Products last announced its quarterly earnings results on June 29th, 2020. The medical device company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.41) by $0.16. Second Sight Medical Products has generated ($1.91) earnings per share over the last year. Second Sight Medical Products has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, August 4th, 2020 based off prior year’s report dates.

Analyst Opinion on Second Sight Medical Products (NASDAQ:EYES)

2 Wall Street analysts have issued ratings and price targets for Second Sight Medical Products in the last 12 months. Their average twelve-month price target is $2.25, suggesting that the stock has a possible upside of 154.52%. The high price target for EYES is $2.50 and the low price target for EYES is $2.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of “Buy.”

Second Sight Medical Products has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $2.25, Second Sight Medical Products has a potential upside of 154.5% from its current price of $0.88. Second Sight Medical Products has received no research coverage in the past 90 days.

Dividend Strength: Second Sight Medical Products (NASDAQ:EYES)

Second Sight Medical Products does not currently pay a dividend. Second Sight Medical Products does not have a long track record of dividend growth.

Insiders buying/selling: Second Sight Medical Products (NASDAQ:EYES)

In the past three months, Second Sight Medical Products insiders have not sold or bought any company stock. 67.52% of the stock of Second Sight Medical Products is held by insiders. A high percentage of insider ownership can be a sign of company health. Only 5.54% of the stock of Second Sight Medical Products is held by institutions.

Earnings and Valuation of Second Sight Medical Products (NASDAQ:EYES

The P/E ratio of Second Sight Medical Products is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Second Sight Medical Products is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Second Sight Medical Products has a P/B Ratio of 1.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

More latest stories: here